US Bancorp DE Sells 12,900 Shares of CVS Health Corporation $CVS

US Bancorp DE decreased its stake in shares of CVS Health Corporation (NYSE:CVS) by 7.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 172,428 shares of the pharmacy operator’s stock after selling 12,900 shares during the quarter. US Bancorp DE’s holdings in CVS Health were worth $12,999,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in CVS. Colonial Trust Advisors raised its holdings in CVS Health by 130.1% in the 3rd quarter. Colonial Trust Advisors now owns 573 shares of the pharmacy operator’s stock valued at $43,000 after acquiring an additional 324 shares in the last quarter. Waddell & Associates LLC acquired a new position in shares of CVS Health in the third quarter valued at $341,000. TD Asset Management Inc lifted its position in CVS Health by 3.5% in the third quarter. TD Asset Management Inc now owns 1,263,369 shares of the pharmacy operator’s stock worth $95,245,000 after purchasing an additional 42,408 shares during the period. Affinity Investment Advisors LLC boosted its stake in CVS Health by 12.6% during the third quarter. Affinity Investment Advisors LLC now owns 21,616 shares of the pharmacy operator’s stock worth $1,630,000 after buying an additional 2,422 shares in the last quarter. Finally, Parkside Investments LLC raised its stake in shares of CVS Health by 7.5% in the 3rd quarter. Parkside Investments LLC now owns 83,638 shares of the pharmacy operator’s stock valued at $6,305,000 after buying an additional 5,849 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 2.2%

CVS opened at $79.74 on Friday. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The stock has a market capitalization of $101.44 billion, a PE ratio of 57.78, a PEG ratio of 0.83 and a beta of 0.50. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The firm has a 50-day moving average price of $78.39 and a two-hundred day moving average price of $77.21.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. During the same period in the prior year, the firm earned $1.19 earnings per share. CVS Health’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were issued a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.3%. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Sanford C. Bernstein reissued a “market perform” rating and issued a $91.00 target price on shares of CVS Health in a research note on Tuesday, January 6th. Barclays lifted their price objective on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Morgan Stanley raised their target price on CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Royal Bank Of Canada reiterated an “outperform” rating on shares of CVS Health in a research report on Thursday, December 4th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Nineteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $94.91.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.